<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03436303</url>
  </required_header>
  <id_info>
    <org_study_id>HRT14021808</org_study_id>
    <nct_id>NCT03436303</nct_id>
  </id_info>
  <brief_title>The Benefits and Risks of Different Menopausal Hormone Replacement Therapy Regimes in the Treatment of Menopause Syndrome</brief_title>
  <official_title>The Effect and Risk of Conjugated Estrogens Combined With Different Types of Progestin in the Treatment of Menopause Syndrome During Window Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, open‑label, randomized controlled clinical trial to compare the benefits and
      risks of half-dose or standard-dose conjugated equine estrogens(CEE) plus natural
      progesterone or dydrogesterone in menopausal hormone therapy .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open‑label, randomized controlled clinical trial compare the benefits
      and risks of half-dose or standard-dose conjugated equine estrogens(CEE) plus natural
      progesterone or dydrogesterone in menopausal hormone therapy during window phase. 120 Healthy
      postmenopausal women with intact uterus seeking treatment for menopausal symptoms are
      enrolled in this study.Participants are randomized into three groups, the CEE 0.3
      mg/micronized progesterone (MP) 100 mg group; CEE 0.625 mg/MP 100 mg group; CEE 0.625
      mg/dydrogesterone 10 mg group,metabolic parameters,body composition,bone mineral
      density,breast cancer risk factors and life quality will be measure at baseline,one year and
      two year intervention.The investigators hypothesize there may be differences of these
      parameters measured among three groups after intervention.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2014</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomly assigned to three groups: CEE 0.3 mg/micronized progesterone (MP) 100 mg group, CEE 0.625 mg/MP 100 mg group,CEE 0.625 mg/dydrogesterone 10 mg group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>5 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>body fat mass percentage</measure>
    <time_frame>5 minutes</time_frame>
    <description>DEXA method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>breast mammography</measure>
    <time_frame>5 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>glucose</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bone mineral density</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-mental State Examination score</measure>
    <time_frame>5 minutes</time_frame>
    <description>Questionnaire.The score range is 0-30.Total score greater than or equal to 24 points indicates a normal cognition,below this, scores can indicate cognitive impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAD scale</measure>
    <time_frame>5 minutes</time_frame>
    <description>questionnaire to evaluate anxiety and depression.The total score is 0-20.Total score 0-7 is normal,8-10 maybe borderline anxiety or depression,11-20 indicates obvious anxiety or depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Kupperman score</measure>
    <time_frame>5 minutes</time_frame>
    <description>questionnaire to evaluate the menopause symptom.The total score range is 0-63.Total score below 6 is normal,6-15 is mild,16-30 is moderate, above 30 is severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>5 minutes</time_frame>
    <description>ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum creatinine</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum glutamic pyretic transaminase</measure>
    <time_frame>5 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Menopause Syndrome</condition>
  <arm_group>
    <arm_group_label>CEE 0.625 mg/MP 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CEE 0.625 mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CEE 0.3 mg/MP 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CEE 0.3mg/micronized progesterone (MP) 100 mg daily for the last 12 days of every 28 days for two years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CEE 0.625 mg/dydrogesterone 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CEE 0.625 mg/dydrogesterone 10 mg daily for the last 12 days of every 28 days for two years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEE 0.625 mg/MP 100mg</intervention_name>
    <description>CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years</description>
    <arm_group_label>CEE 0.625 mg/MP 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEE 0.3 mg/MP 100mg</intervention_name>
    <description>CEE 0.3 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years</description>
    <arm_group_label>CEE 0.3 mg/MP 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEE 0.625mg/dydrogesterone</intervention_name>
    <description>CEE 0.3 mg/dydrogesterone 10mg daily for the last 12 days of every 28 days for two years</description>
    <arm_group_label>CEE 0.625 mg/dydrogesterone 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 40 and 60 years old;

          2. natural amenorrhea for more than 6 months but less than 5 years;

          3. suffered by menopause symptoms and seeking for treatment;

          4. serum follicle‑stimulating hormone levels &gt;40 IU/L and serum estradiol &lt;30 pg/ml.

        Exclusion Criteria:

          1. contraindications for menopausal hormone therapy;

          2. complications including: uterine myoma more than 3 centimeter in diameter,
             endometriosis, uncontrolled hypertension or diabetes mellitus, thromboembolic disease
             history or high risk for developing thromboembolic disease, epilepsy, asthma,
             hyperprolactinemia, first degree relative has breast cancer;

          3. cardiovascular, chronic liver, thyroid or kidney diseases; a history of cancer; a
             disease or condition that could influence the participants' ability to follow the
             study protocol;

          4. alcohol or drug abuse within the last 3 months;

          5. use of hormone therapy in the past 3months;

          6. endometrial thickness more than 5mm even after progestin withdrawal;

          7. abnormal cervical scraping smear;

          8. allergic to any ingredient of the drugs;

          9. participation in other clinical trials within the last 6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>female</gender_description>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aijun Sun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital,Peking Union Medical College, Chinese Academy of Medicine Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>China/Beiing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Thorneycroft IH, Lindsay R, Pickar JH. Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. Am J Obstet Gynecol. 2007 Aug;197(2):137.e1-7.</citation>
    <PMID>17689624</PMID>
  </reference>
  <reference>
    <citation>Margolis KL, Bonds DE, Rodabough RJ, Tinker L, Phillips LS, Allen C, Bassford T, Burke G, Torrens J, Howard BV; Women’s Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia. 2004 Jul;47(7):1175-1187. doi: 10.1007/s00125-004-1448-x. Epub 2004 Jul 14.</citation>
    <PMID>15252707</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2018</study_first_posted>
  <last_update_submitted>February 10, 2018</last_update_submitted>
  <last_update_submitted_qc>February 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Aijun Sun</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Menopause Syndrome</keyword>
  <keyword>low dose estrogen</keyword>
  <keyword>progestin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Progestins</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Network platform, and the website will be attached later.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

